Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that at the Board Meeting held today i.e. on Friday, 30th May, 2025, and have Considered and approved the Audited Standalone and Consolidated Financial Results for the Quarter and Financial Year ended 31st March, 2025. The said Audited Financial Results were reviewed by Audit Committee and thereafter approved by the Board of Directors.

pdf

ANG Lifesciences India Ltd.

22 May 2025

28.02

-4.50%

Company Update

ANG Lifesciences India Ltd - 540694 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Pursuant to Regulation 24(A) of SEBI(LODR), Regulations, 2015, enclosed is the Annual Secretarial Compliance Report for the year ended on 31.03.2025

pdf

ANG Lifesciences India Ltd.

22 May 2025

28.02

-4.50%

Board Meeting

ANG Lifesciences India Ltd - 540694 - Board Meeting Intimation for Intimation Of Board Meeting Pursuant …

BSE India

ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve Pursuant to the Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, It is hereby informed you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, 30th May, 2025 at 05:30 P.M. at the Registered Office of the Company situated at Darbara Complex, SCO-113, District Shopping Centre, B Block, Ranjit Avenue, Amritsar-143001, inter alia transact the following business: 1. To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended 31st March, 2025. 2. Any other business that may be necessary with the permission of Chairman.

pdf

ANG Lifesciences India Ltd.

24 Apr 2025

28.02

-4.50%

Company Update

ANG Lifesciences India Ltd - 540694 - Disclosure Of Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated …

BSE India

The company is not falling under Large Corporate Category as on 31st March, 2025.

pdf

ANG Lifesciences India Ltd.

24 Apr 2025

28.02

-4.50%

Corp. Note

ANG Lifesciences India Ltd - 540694 - Format of the Initial Disclosure to be made by …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyANG Lifesciences India Ltd 2CIN NO.L24230PB2006PLC030341 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harshita Aggarwal Designation: Company Secretary EmailId: cs@anglifesciences.com Name of the Chief Financial Officer: Saruchi Gupta Designation: CFO EmailId: saruchigupta1977@gmail.com Date: 24/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

ANG Lifesciences India Ltd.

22 Apr 2025

28.02

-4.50%

Company Update

ANG Lifesciences India Ltd - 540694 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Compliance certificate under Reg 74(5) of SEBI (DP) Regulations, for quarter ended 31.03.2025.

pdf

Is ANG Lifesciences India Ltd. worth buying?

61 Votes:

Buy 77.05%

Sell 11.48%

Hold 11.48%